Sequencing in Evolved Urothelial Carcinoma

— Navigating 2nd-line alternate choices

by Greg Laub, Director, Video, MedPage Nowadays November 1, 2024

The indication for sacituzumab govitecan (Trodelvy) in beforehand treated patients with in the community developed or metastatic urothelial cancer turned into withdrawn closing month after the drug didn’t crimson meat up survival versus single-agent chemotherapy in the segment III TROPiCS-04 trial.

In gentle of this modified landscape, Joaquim Bellmunt, MD, PhD, of Dana-Farber Cancer Institute in Boston, discusses 2nd-line treatment alternate choices.

Following is a transcript of his remarks:

Sequencing is now a problem on memoir of we now dangle now, as talked about, three alternate choices for first-line treatment and the level is what to construct subsequent. And then in patients who’re receiving chemotherapy followed by maintenance avelumab [Bavencio]after that some patients are receiving enfortumab vedotin [EV, Padcev]after which after that receiving sacituzumab govitecan. That is the latest sequencing on that.

In patients who’re receiving EV/[pembrolizumab (Keytruda)]then clearly the most rational subsequent step — and without any data supporting that — we are giving cisplatin on memoir of we now dangle no longer been utilizing the cisplatin in first-line treatment.

Earlier than this ASCO [American Society of Clinical Oncology]one more thing that has no longer been offered is, we heard the press liberate of the TROPiCS-04that is the sacituzumab segment III. Unfortunately, this trial turned into negative. And this will seemingly be very relating on memoir of now we were going to dangle one more drug, an ADC [antibody-drug conjugate] sacituzumab govitecan, for sequencing.